Get started
Live feed
·
PRReleasevia Quantisnow
Calidi Biotherapeutics Inc. logo

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for CLDI

Across the 27 sessions after earlier CLDI headlines, the stock closed higher 10 times and lower 16 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

CLDI close-to-close change in the session after earlier headlines
SessionEarlier headlineCLDISPY
Jul 27, 2026Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference+9.5%+0.0%
Jul 21, 2026Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Driversand 1 other headline that session-13.9%+0.8%
Jul 9, 2026Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711+5.3%+0.8%
Jun 24, 2026Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit+0.6%-0.0%
Jun 16, 2026Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study-1.9%-0.6%
Jun 8, 2026Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026+3.6%+0.2%
Quantisnow market dataAMEX
Calidi Biotherapeutics Inc. logo
CLDI
Calidi Biotherapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2021
Get push alerts for CLDI

Follow CLDI and get a push notification the moment its next story breaks.

Full CLDI profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDI (Calidi Biotherapeutics Inc.) and more on Quantisnow.